
Kaden Coziar
Founder & Managing Editor, The RX Index
Research editor — not a physician or medical provider
Kaden Coziar is the founder and managing editor of The RX Index. He edits and takes responsibility for The RX Index Research, the site's independent collection of trackers, datasets, and policy reviews on GLP-1 medications.
Research areas
- GLP-1 access and prescribing channels
- Prescription-drug pricing and payment programs
- Insurance coverage, including Medicaid, Medicare, employer, and ACA Marketplace plans
- FDA regulatory policy, compounding rules, and enforcement records
- Patents, generic entry, shortages, and prescription-drug market data
Role and responsibility
Kaden is the named author of every research asset listed below. For each one he is responsible for source selection, verification against primary records, dated releases, the methodology notes, and corrections. Research pages state when each finding was last verified and what the evidence does and does not establish.
Kaden is an editor and researcher. He is not a physician, pharmacist, or other licensed healthcare provider, and his work is not medical advice. When a page has been reviewed by a clinician, it names that medical reviewer, their credentials, and the review date separately from the author byline, as described in the medical review policy.
Consumer guides, comparisons, and provider reviews elsewhere on the site are published under the RX Index Editorial Team byline.
How the research is produced
- Findings are drawn from primary sources where available: state Medicaid and plan documents, CMS and FDA records, court dockets, manufacturer filings, and peer-reviewed trials.
- Secondary analyses (for example KFF or industry surveys) are labeled as such and dated.
- Material changes are released as dated versions. Where a dataset is published, it comes with downloadable files and citation formats.
- Methods are documented in the research methodology, and revisions are logged in the research changelog.
Financial interest disclosure
As founder, Kaden has a financial interest in The RX Index. The site earns affiliate commissions from some links in its consumer guides; see the affiliate disclosure. Research pages carry no affiliate links. Where they link to a related consumer guide, that link is labeled and kept separate from the findings.
Citing and contacting
Suggested citation format for research assets:
Coziar, Kaden. “[Title].” The RX Index Research. [Release or update date]. [URL].
Journalists, researchers, and readers can reach Kaden at hello@therxindex.com. To report an error, see the corrections policy.
Research by Kaden Coziar (29)
Coverage & access
- GLP-1 Prior Authorization Requirements by Insurer
Plan criteria, documentation, and authorization requirements.
- ACA Marketplace GLP-1 Coverage by Carrier and State
Marketplace coverage evidence by carrier and state.
- Medicaid Managed Care GLP-1 Coverage by Plan
Managed-care rules alongside state Medicaid policy.
- GLP-1 Telehealth Prescribing Practices
Research on prescribing practices and the limits of public evidence.
- GLP-1 Medicaid Coverage by State
State Medicaid coverage policies and documented changes.
- GLP-1 Employer Coverage Tracker
Employer-plan decisions and survey evidence.
Pricing & market data
- GLP-1 Statistics
Usage, cost, and coverage measures with their source definitions.
- GLP-1 Price & Access Tracker
Manufacturer prices and payment channels.
- GLP-1 Pricing by Country
International prices and differences between payment systems.
- GLP-1 Manufacturer Financials
Company-reported revenue and financial reporting periods.
Medicare & public programs
- BALANCE Model Medicaid Participating States
Public records of state participation and policy status.
- Medicare Part D GLP-1 Coverage by Plan
Part D coverage routes and program distinctions.
- Kansas SEHP GLP-1 Prior Authorization Requirements
Kansas state-employee plan requirements, not a nationwide plan census.
- Medicare GLP-1 Prescriptions by State
State-level Medicare prescription and spending data.
- Medicare GLP-1 Bridge Tracker
Program rules, covered formulations, and eligibility distinctions.
Regulation & enforcement
- Compounded GLP-1 Laws by State
State rules and federal compounding distinctions.
- Counterfeit GLP-1 Incidents Tracker
Regulator notices and reported counterfeit incidents.
- Compounded GLP-1 Enforcement Tracker
Regulatory actions concerning compounded GLP-1 products.
- GLP-1 Lawsuits & Enforcement Tracker
Court proceedings and regulatory actions, kept distinct.
Patents, generics & supply
- GLP-1 Patent Expiration Tracker
Patents, exclusivity, filings, and generic-entry distinctions.
- Generic Semaglutide Availability by Country
Country-level approval and market-availability records.
- GLP-1 Shortage Tracker
Shortage records and availability distinctions.
Clinical evidence & safety data
- GLP-1 Clinical Trial Demographics
Who participated in the included clinical trials.
- GLP-1 Clinical Trial Exclusion Criteria
Trial eligibility restrictions and limits to generalization.
- GLP-1 Lean Mass Loss by Drug
Trial-level body-composition evidence and measurement differences.
- GLP-1 FDA Label Changes
Documented changes to approved product labeling.
- GLP-1 Adverse Event Reports
Reported-event datasets and their interpretation limits.
- MACE in GLP-1 Cardiovascular Trials
Cardiovascular trial endpoints and interpretation.
- GLP-1 Pancreatitis Risk
Evidence and safety context for pancreatitis concerns.